36093-97-7

Usage

Uses

Used in Pharmaceutical Industry:
(2-P-Tolyl-thiazol-4-yl)-methanol is used as a key intermediate in the synthesis of new drugs, contributing to the development of innovative pharmaceuticals with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, (2-P-Tolyl-thiazol-4-yl)-methanol serves as a building block for the creation of novel agrochemicals, enhancing crop protection and yield.
Used in Organic Chemical Reactions:
(2-P-Tolyl-thiazol-4-yl)-methanol is utilized as a reactant in various organic chemical reactions, facilitating the synthesis of a wide range of functional materials and specialty chemicals.
Used in Development of Novel Chemical Entities:
Due to its unique structure and potential biological activity, (2-P-Tolyl-thiazol-4-yl)-methanol is employed as a starting material in the development of new chemical entities with diverse applications across different fields.

InChI:InChI=1S/C11H11NOS/c1-8-2-4-9(5-3-8)11-12-10(6-13)7-14-11/h2-5,7,13H,6H2,1H3

Upstream product

• 35199-18-9 4-chloromethyl-2-(4-methyl-phenyl)-thiazole 
• 2362-62-1 4-methylthiobenzamide 
• 104-85-8 para-methylbenzonitrile 
• 132089-32-8 2-(4'-methylphenyl)-4-carbethoxythiazole 

Downstream Products

• 52041-82-4 (5-bromo-2-p-tolyl-thiazol-4-yl)-methanol 
• 17228-99-8 2-(p-tolyl)thiazole-4-carboxylic acid 
• 52041-92-6 5-bromo-2-p-tolyl-thiazole-4-carbaldehyde 
• 52041-96-0 5-bromo-2-p-tolyl-thiazole-4-carboxylic acid 
• 940830-05-7 piperidin-1-yl(2-p-tolylthiazol-4-yl)methanone 
• 55327-29-2 2-p-tolylthiazole-4-carbaldehyde 
• 16207-01-5 1-((2-p-tolylthiazol-4-yl)methylene)thiosemicarbazide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells

Mitochondria are pivotal energy production sources for cells to maintain necessary metabolism activities. Targeting dysfunctional mitochondrial features has been a hotspot for mitochondrial-related disease researches. Investigation with cancerous mitochondrial metabolism is a continuing concern within tumor therapy. Herein, we set out to assess the anti-cancer activities of a novel family of TPP-thiazole derivatives based on our earlier research on mitochondrial targeting agents. Specifically, we designed and synthesized a series of TPP-thiazole derivatives and revealed by the MTT assay that most synthesized compounds effectively inhibited three cancer cell lines (HeLa, PC3 and MCF-7). After structure modifications, we explored the SAR relationships and identified the most promising compound R13 (IC50 of 5.52 μM) for further investigation. In the meantime, we performed ATP production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

Synthesis of new 2-(thiazol-4-yl)thiazolidin-4-one derivatives as potential anti-mycobacterial agents

To search for potent antimycobacterial lead compounds, a new series of 3-substituted phenyl-2-(2-(substituted phenyl)thiazol-4-yl) thiazolidin-4-one (5a-t) derivatives have been synthesized by the condensation of 2-substituted phenyl thiazole-4-carbaldehy

Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives

The increase in antibiotic resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis Bacille Calmette Guerin (ATCC 35743) strains. The synthesized compounds, 5a–l were further assayed for their cytotoxic activity against the two human cancer cell lines, HeLa and human colon carcinoma 116 cell lines and showed no significant cytotoxic activity against these two cell lines at the maximum concentration evaluated. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimycobacterial agent.

Synthesis, cytotoxicity assessment, and molecular docking of 4-substituted-2-p-tolylthiazole derivatives as probable c-Src and erb tyrosine kinase inhibitors

In the current project we focused on the synthesis of 4-Substituted-2-p- tolylthiazole derivatives. Cytotoxicity of synthesized compounds were evaluated against T47D breast cancer cell line and also all of the final compounds 3-7 were docked into the active site of c-Src and erb tyrosine kinases. Compound 4 was the most potent derivative in cytotoxicity assay (IC50 = 2.5 μg/mL) and it was also the most potent inhibitor of erb tyrosine kinase (Binding free energy: -10.18 kcal/mol).